The Latest Cardiac and Vascular News
BOSTON – Danvers-based Abiomed, Inc. has agreed to pay $3.1 million to resolve allegations that it violated the False Claims Act by purchasing lavish meals for physicians in order to induce them to use Abiomed’s Impella line of heart pumps. The United States contends that Abiomed sought to induce physicians to use its pumps, which cost more than $20,000 each, by buying meals for […]
Abiomed Receives Approval for Expanded FDA Indication for High Risk Percutaneous Coronary Intervention (PCI) Procedures DANVERS, Mass., Feb. 14, 2018 (GLOBE NEWSWIRE) — Abiomed(Nasdaq:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced that it has received an expanded U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for the […]
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) — Abiomed(NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new indication and Women’s Initiative focused on heart recovery education and awareness. This Women’s Initiative is in conjunction with the Company’s expanded FDA approval for cardiogenic […]
DANVERS, Mass., Jan. 12, 2018 (GLOBE NEWSWIRE) — Abiomed(NASDAQ:ABMD) announced that on Thursday, February 1, 2018, the Company will release financial results for the third quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, February 1, 2018, at 8:00 a.m. EST. Michael R. […]
Maquet files new patent infringement dispute based on a patent from earlier this year Maquet opens a new front in patent war with Abiomed NOVEMBER 28, 2017 BY BRAD PERRIELLO, MassDevice Getinge (PINK:GETI B) subsidiary Maquet opened a new front last week in its patent war with Abiomed (NSDQ:ABMD), alleging infringement of a patent granted earlier this […]
DANVERS, Mass., Oct. 19, 2017 (GLOBE NEWSWIRE) — Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announces that there are more than 30 presentations potentially featuring the Impella® line of heart pumps scheduled during the 29th Transcatheter Cardiovascular Therapeutics (TCT) conference, the annual scientific symposium of […]
DANVERS, Mass., Oct. 10, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD) announced that on Thursday, October 26, 2017, the Company will release financial results for the second quarter of fiscal 2018. The Company will host a conference call to discuss the results on Thursday, October 26, 2017, at 8:00 a.m. EDT. […]
TEL-AVIV, Israel, September 28, 2017 /PRNewswire/ — Magenta Medical, a medical device company in the field of transcatheter heart failure therapy, announced today the successful closing of its $15M series B financing round. The syndicate of investors is comprised of Abiomed Inc., a leader in transcatheter heart pumps, Pitango Venture Capital, among Israel’s leading venture capital […]
DANVERS, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, today announced it has received U.S. Food and Drug Administration (FDA) pre-market approval (PMA) for the Impella RP® heart pump. Culminating from five years of research, this approval follows the […]
DANVERS, Mass., Aug. 28, 2017 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today that it has accepted the resignation of its Chief Financial Officer, Michael Tomsicek, effective August 24, 2017. After two years, Mr. Tomsicek is leaving the Company to pursue other […]
